Amgen

$251.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$7.54 (-2.92%) Today

-$0.06 (-0.02%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Amgen and other stocks, options, and ETFs commission-free!

About AMGN

Amgen Inc. Common Stock, also called Amgen, is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA. The listed name for AMGN is Amgen Inc. Common Stock.

CEO

Robert A. Bradway

Employees

23,400

Headquarters

Thousand Oaks, California

Founded

1980

Market Cap

143.28B

Price-Earnings Ratio

20.74

Dividend Yield

2.49

Average Volume

2.41M

High Today

$259.44

Low Today

$250.32

Open Price

$255.31

Volume

3.24M

52 Week High

$264.97

52 Week Low

$177.05

Collections

AMGN News

MarketWatchJan 21

BioNTech SE ADR rises Thursday, outperforms market

The BioNTech SE ADR BNTX, +2.13% rallied 2.13% to $105.43 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P

Analyst Ratings

47%

of 30 ratings

Buy

47%

Hold

50%

Sell

AMGN Earnings

$0.00

$1.46

$2.91

$4.37

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Available Feb 2, After Hours